SynAct Pharma AB (STO:SYNACT)
Sweden · Delayed Price · Currency is SEK | Market Cap | 895.97M -21.1% |
| Revenue (ttm) | n/a |
| Net Income | -106.14M |
| EPS | -1.97 |
| Shares Out | 56.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 186,848 |
| Open | 16.08 |
| Previous Close | 16.22 |
| Day's Range | 15.18 - 16.08 |
| 52-Week Range | 7.05 - 24.50 |
| Beta | 0.83 |
| Analysts | n/a |
| Price Target | 34.70 (+116.88%) |
| Earnings Date | Nov 3, 2026 |
About SynAct Pharma AB
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis; host targeted treatment for viral infections such as respiratory infections, dengue virus, as well as polymyalgia rheumatica (PMR); and idiopathic membranous nephropathy. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ fa... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
The average 12-month stock price target for SYNACT is kr 34.70, which is an increase of 116.88% from the latest price.
News
SynAct Pharma AB Transcript: Investing in Life Science 2026
The company is advancing inflammation therapies with a strong IP position, a seasoned team, and a robust pipeline led by a phase III-ready RA asset. Key partnerships in Brazil and ongoing studies in dengue and influenza support near-term milestones, with strong financial backing through 2027.
SynAct Pharma AB Slides: Company presentation
SynAct Pharma AB has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2026.
SynAct Pharma AB Quarterly report: Q2 2026
SynAct Pharma AB has published its Q2 2026 quarterly earnings report on August 20, 2026.
SynAct Pharma AB Slides: Company presentation
SynAct Pharma AB has posted slides in relation to its latest quarterly earnings report, which was published on June 29, 2026.
SynAct Pharma AB Transcript: Study result
The phase II-B ADVANCE study showed that 40 mg resomelagon, combined with methotrexate, achieved strong ACR20 and ACR50 responses and significant reductions in inflammation markers in early RA patients, with a favorable safety profile and no immunosuppression. These results support phase III development and strategic partnering discussions.
SynAct Pharma AB Press release: Study result
SynAct Pharma AB issued a press release on June 15, 2026, disclosing material business information to investors.
SynAct Pharma AB Transcript: Aktiedagarna 2026
The company is advancing a novel, non-immunosuppressive oral therapy for immune diseases, with phase II-B data in rheumatoid arthritis expected soon. Success could open broad market opportunities and lead to partnerships for phase III and commercialization.
SynAct Pharma AB Quarterly report: Q1 2026
SynAct Pharma AB has published its Q1 2026 quarterly earnings report on May 27, 2026.
SynAct Pharma AB Slides: Company presentation
SynAct Pharma AB has posted slides in relation to its latest quarterly earnings report, which was published on April 16, 2026.
SynAct Pharma AB Transcript: CMD 2026
Key clinical data from three programs are expected in the next two quarters, driving a shift to active business development. The lead RA program targets early, high-activity patients with a novel, non-immunosuppressive therapy, while host-directed therapies for respiratory infections address major unmet needs. Strong financials and a dual-track strategy support broad partnering opportunities.
SynAct Pharma AB Quarterly report: Q4 2025
SynAct Pharma AB has published its Q4 2025 quarterly earnings report on February 18, 2026.
SynAct Pharma AB Annual report: Q4 2025
SynAct Pharma AB has published its Q4 2025 annual report on February 18, 2026.
SynAct Pharma AB Slides: Company presentation
SynAct Pharma AB has posted slides in relation to its latest quarterly earnings report, which was published on February 8, 2026.
SynAct Pharma AB Transcript: Life Science Summit 2025
Resomelagon is advancing in phase IIB trials for rheumatoid arthritis and host-directed viral infection therapies, with major data readouts and a dengue study expected next year. The approach targets immune modulation, aiming to improve outcomes and reduce side effects.